User profiles for K. Vishwanathan

Kala Visvanathan

- Verified email at jhu.edu - Cited by 46509

Karthik Vishwanathan

- Verified email at paruluniversity.ac.in - Cited by 564

Michael addition reactions in macromolecular design for emerging technologies

BD Mather, K Viswanathan, KM Miller… - Progress in Polymer …, 2006 - Elsevier
… the value of K eq is highly dependent on the relative base strength. For strong bases, K eq
will … (5), there is a pseudo first-order dependence on acrylate concentration, where k obs is a …

[HTML][HTML] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

…, H Mann, KS Thress, MM Frigault, K Vishwanathan… - Annals of …, 2020 - Elsevier
Background Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study (NCT02143466) was …

Development of combined infrared and hot air dryer for vegetables

HU Hebbar, KH Vishwanathan, MN Ramesh - Journal of food engineering, 2004 - Elsevier
… absolute temperature of the heating chamber wall outer surface, K … (9) Energy =K e × AV ×
Δ T The infrared energy input for drying was estimated based on the power input and duration …

ZnO nanostructures in active antibacterial food packaging: preparation methods, antimicrobial mechanisms, safety issues, future prospects, and challenges

I Kim, K Viswanathan, G Kasi… - Food Reviews …, 2022 - Taylor & Francis
Packaging of food products is one of the most important stages of the food supply chain.
Nano-size materials for packing food substances with appropriate properties result in better …

Keap1–nrf2 signaling: a target for cancer prevention by sulforaphane

…, PA Egner, AS Agyeman, K Visvanathan… - Natural products in …, 2013 - Springer
Sulforaphane is a promising agent under preclinical evaluation in many models of disease
prevention. This bioactive phytochemical affects many molecular targets in cellular and …

[HTML][HTML] Osimertinib in patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer and leptomeningeal metastases: the BLOOM study

…, B Collins, J Chmielecki, K Vishwanathan… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical …

…, E Felip, P Leese, M Cantarini, K Vishwanathan… - Cancer Chemotherapy …, 2016 - Springer
Purpose Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment
of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously …

Infrared assisted dry-blanching and hybrid drying of carrot

KH Vishwanathan, GK Giwari, HU Hebbar - Food and Bioproducts …, 2013 - Elsevier
Infrared (IR) blanching and IR assisted hot air (hybrid) drying of carrot slices were attempted
and their performance (processing time, retention of vitamin C and rehydration …

Upper limb muscle imbalance in tennis elbow: a functional and electromyographic assessment

…, AC Fisher, GJ Kemp, K Vishwanathan… - Journal of …, 2007 - Wiley Online Library
The purpose of this study was to investigate strength, fatigability, and activity of upper limb
musculature to elucidate the role of muscular imbalance in the pathophysiology of tennis …

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

…, R de Greef, K Vishwanathan… - British Journal of …, 2017 - Wiley Online Library
… where Pj is the jth population estimate of parameters, Xij the covariate of patient i for
parameter P j , θ k the typical value of parameter P j , θ i a coefficient that reflects the covariate's …